News Releases



American Association for Cancer Research and Bayer Partner to Fund Fellowships to Advance Cancer Research12780865/27/2015 2:18:19 PM Releases/AllItems.aspx731False2015-05-27T14:00:00Z<div class="ExternalClassFF54D814FD13461189CACA71E68EEE15"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) and <a href="http&#58;//" target="_blank">Bayer HealthCare</a>&#160;are pleased to announce a new partnership that will expand the AACR’s Basic Cancer Research Fellowship Program for 2015.</p><p>The AACR-Bayer HealthCare Basic Cancer Research Fellowships represent a joint effort to provide critical support to postdoctoral and clinical fellows conducting basic cancer research at the earliest stages of their careers. Two fellowships are being provided through this partnership. </p><p>“The AACR is excited to partner with Bayer to help young scientists develop their careers and to broaden our fundamental understanding of cancer through basic research,” said Mitch Stoller, executive director of the <a href="https&#58;//" target="_blank">AACR Foundation</a>. “At the start of their careers, researchers are particularly vulnerable to the current funding crisis for biomedical research and the AACR is committed to supporting these young investigators whose discoveries will drive progress against the more than 200 diseases we call cancer.”</p><p>The expansion of this program is significant, as it is one of the most highly competitive fellowships offered by the AACR. Bayer’s commitment to funding these additional fellowships will ensure that more talented young investigators have the necessary resources to explore their innovative research ideas.</p><p>“We are pleased to offer these two grants as part of our new partnership with the American Association for Cancer Research and support talented young investigators to explore their innovative approaches in basic cancer research and help increase understanding in tumor biology,” said Karl Ziegelbauer, PhD, head of therapeutic research groups at Bayer HealthCare. “Our collaboration with the AACR underscores Bayer’s continuous commitment to advancing research in the field of oncology.”</p><p>The 2015 recipients of the AACR-Bayer HealthCare Basic Cancer Research Fellowships are Mario A. Shields, PhD, Cold Spring Harbor Laboratory in Cold Spring Harbor, New York, and Michelle P. Cicchini, PhD, the University of Pennsylvania in Philadelphia.</p><p>Each grant will provide $55,000 for one year, beginning July 1, 2015.&#160;&#160;&#160; </p><p>The AACR and Bayer will continue their partnership in 2016, where two new fellowship opportunities will be available&#58; the AACR-Bayer HealthCare Prostate Cancer Research Fellowship and the AACR-Bayer HealthCare Hepatocellular Carcinoma Research Fellowship. <br>The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to either prostate cancer or hepatocellular carcinoma. These funding opportunities will be open to applications in the fall of 2015. All decisions regarding the review and selection of the submitted applications will be made by the AACR Scientific Review Committee in accordance with the policies and procedures of the AACR.</p><p>Further details about the 2016 fellowships will be <a href="/FUNDING/PAGES/DEFAULT.ASPX">available online </a>later this year. Additional inquiries may be directed to Ashley Jones at <a href="mailto&#58;"></a>. </p></div>
​AACR CEO Margaret Foti Recognized as 2015 Honoree of "the one hundred" by Massachusetts General Hospital Cancer Center12750605/27/2015 4:09:21 PM Releases/AllItems.aspx730False2015-05-27T13:00:00Z<div class="ExternalClass69463BED5BA84A58B8B3DE04C523FBBA"><p>PHILADELPHIA — Margaret Foti, PhD, MD (hc), chief executive officer (CEO) of the American Association for Cancer Research (AACR), was <a href="https&#58;//" target="_blank">honored</a> for her “dedication and commitment to solving cancer through research” and for her “passionate advocacy for increased federal funding for cancer research and biomedical science” at Massachusetts General Hospital Cancer Center’s eighth annual “one hundred” gala, held last night at the Westin Copley Place Hotel in Boston.</p><p><img src="/PublishingImages/Foti_One_Hundred_250x268.jpg" alt="" style="margin&#58;5px 10px;vertical-align&#58;auto;float&#58;right;" /><a href="http&#58;//" target="_blank">Massachusetts General Hospital Cancer Center</a> established <a href="https&#58;//" target="_blank">the one hundred</a> as an awareness and fundraising initiative that celebrates hope in the cancer community. Each year, 100 individuals and groups—caregivers, researchers, philanthropists, advocates, and volunteers from around the world—whose commitment to the fight against cancer inspires others to take action are selected through a public nomination process and celebrated at a spring gala in Boston.</p><p>“I am deeply honored to be recognized by Massachusetts General Hospital Cancer Center as a 2015 honoree of the one hundred,” said Foti. “It is really humbling for me to share this recognition with so many inspiring women, men, children, and organizations that have made remarkable contributions to this important cause. The personal stories of the one hundred honorees are a testament to the courage and strength of purpose shown by those who have faced a cancer diagnosis and by those who have provided vital support to others in their fight against cancer. Working collaboratively with individuals and organizations like these is a cornerstone of the AACR’s mission, because if we are to accelerate the pace of progress against the insidious group of diseases we call cancer, we must bring together people and organizations from around the globe.”</p><p>During Foti’s tenure as CEO of the AACR, her leadership has been instrumental in increasing the organization’s membership, which has grown from about 3,000 to 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 101 countries. In addition, the organization’s comprehensive program of national and international conferences and educational workshops has flourished, with attendance at the AACR Annual Meeting 2015 reaching a record-breaking high of nearly 19,300. Foti’s efforts to accelerate the dissemination of new research findings among scientists and others dedicated to the conquest of cancer have included expanding the AACR’s portfolio of peer-reviewed scientific journals from one to eight&#58; <em>Cancer Discovery</em>; <em>Cancer Research</em>; <em>Clinical Cancer Research</em>; <em>Molecular Cancer Therapeutics</em>; <em>Cancer Prevention Research</em>; <em>Molecular Cancer Research</em>; <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>; and <em>Cancer Immunology Research</em>.</p><p>Under Foti’s guidance, the AACR has become an outspoken proponent of policies that support all aspects of cancer research and prevention. The organization engages with policymakers through its Science Policy and Government Affairs Committee and Washington, D.C., office, which opened in 2007 to amplify the voice of cancer researchers, patients, survivors, and caregivers on Capitol Hill. The AACR’s commitment to advocacy is evident through the leading role it plays in organizing the annual Rally for Medical Research Hill Day, which raises awareness among the nation’s policymakers about the need to make funding for the National Institutes of Health a national priority and the importance of continued investment in medical research.</p><p>Foti also leads the AACR’s scientific partnership with Stand Up To Cancer (SU2C), a charitable initiative that supports groundbreaking translational research aimed at getting new cancer treatments to patients in an accelerated time frame. The AACR plays an integral role by providing expert peer review, grants administration, and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit.</p><p>Foti’s contributions have been widely recognized by numerous awards from organizations around the world. Her extensive list of formal recognitions includes honorary degrees in medicine and surgery from the University of Rome La Sapienza and the University of Catania in Sicily, and an honorary degree in medicine from the University CEU of San Pablo in Madrid. Most recently, she received the Children’s Champion Award from Children’s Hospital of Philadelphia in 2015, the 2014 Ellen V. Sigal Advocacy Leadership Award from Friends of Cancer Research, the 2014 Morton M. Kligerman Visiting Professorship Award from the University of Pennsylvania, the 2013 Stanley P. Reimann Honor Award from Fox Chase Cancer Center, and the 2013 Distinguished Partner in Hope Award during the Annual Colorectal Cancer Conference hosted by the Abramson Cancer Center of the University of Pennsylvania.</p></div>
Nominations Open for 2015 AACR Distinguished Lectureship on the Science of Cancer Health Disparities12222965/13/2015 8:48:11 PM Releases/AllItems.aspx729False2015-05-14T13:00:00Z<div class="ExternalClassCC0587F6241344A799601DD8CC6A5C68"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) has issued a call for nominations for its 2015 Distinguished Lectureship on the Science of Cancer Health Disparities, funded by Susan G. Komen.</p><p>The sixth annual <a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=10">AACR Distinguished Lectureship on the Science of Cancer Health Disparities</a>, funded by Susan G. Komen, will recognize an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of cancer health disparities.</p><p>The recipient of this year’s award will receive a $5,000 honorarium and present a 45-minute lecture at the eighth annual <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=68">AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved</a>, to be held Nov. 13-16, in Atlanta.</p><p>The 2014 award recognized <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=618">John D. Carpten, PhD</a>, deputy director of basic sciences at the Translational Genomics Research Institute (TGen) in Phoenix, for his outstanding research focused on understanding the role of biology in the disparate cancer incidence and mortality rates seen among minority populations. Carpten delivered his award lecture titled, “Genetics and Genome Sciences in Cancer Health Disparities.”</p><ul><li>Extended deadline for nominations&#58; May 27, 2015</li><li>For more information, contact Monique P. Eversley at <a href="mailto&#58;"></a> or visit the lectureship’s <a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=10">information page</a>. </li></ul></div>
First-in-class Antibody Mixture Shows Clinical Activity Against Treatment-resistant, Advanced Colorectal Cancer12091705/11/2015 1:57:44 PM Releases/AllItems.aspx728False2015-05-11T04:05:00Z<div class="ExternalClass2F6868F866434590AFBBD9AB7796991A"><p>PHILADELPHIA — Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies, was found to be clinically active in patients with advanced colorectal cancer that had become resistant to prior anti-EGFR therapies, according to a <a href="http&#58;//" target="_blank">study</a> published in <em>Cancer Discovery</em>, a journal of the American Association for Cancer Research. <img alt="Josep Tabernero, MD, PhD" src="/PublishingImages/Tabernero_Josep_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>“This study represents one of the first examples of promising translation from preclinical findings to drug development and clinical activity against anti-EGFR antibody-resistant colorectal cancer,” said <a href="http&#58;//" target="_blank">Josep Tabernero, MD, PhD</a>, head of the medical oncology department at <a href="http&#58;//" target="_blank">Vall d’Hebron University Hospital</a> and director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. “The significant antitumor activity of Sym004 in patients whose tumors have become resistant to anti-EGFR therapies suggests that some colorectal cancers that progress after treatment with cetuximab or panitumumab [anti-EGFR therapies] remain dependent on EGFR signaling.”</p><p>Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options, explained Tabernero. Over the last decade, some of the mechanisms driving resistance have been identified, but despite intensive research, treatment options available for patients have not improved, he added. </p><p>“Sym004 is a 1&#58;1 mixture in the same infusion bag of two antibodies that bind to different regions of the extracellular domain of EGFR,” Tabernero said. Like the U.S. Food and Drug Administration (FDA)-approved anti-EGFR antibodies cetuximab and panitumumab, Sym004 antibodies block EGFR. However, the double-targeting of EGFR by Sym004 causes superior EGFR internalization and degradation, which is likely to provide better outcomes than cetuximab or panitumumab, he explained.</p><p>Tabernero and colleagues enrolled 62 patients to a <a href="https&#58;//;rank=1" target="_blank">phase I study</a>; 20 patients with advanced solid epithelial tumors were enrolled to the dose-escalation phase of the study and received different doses of Sym004, ranging from 0.4 mg/kg to 12 mg/kg, administered weekly. The remaining 42 patients had metastatic colorectal cancer and had previously been treated with anti-EGFR antibodies with brief responses, and were enrolled to the dose-expansion phase of the trial. Patients in the dose-expansion cohort received weekly doses of 9 mg/kg or 12 mg/kg of Sym004.</p><p>Of the patients in the dose-expansion cohort, five (13 percent) had a partial response, and overall, 17 (44 percent) had some degree of tumor shrinkage during treatment with Sym004, according to Tabernero. The overall disease-control rate, which includes partial responses and stable disease, was 67 percent.</p><p>Tabernero said that the toxicity profile was consistent with the experience from FDA-approved anti-EGFR antibodies (grade 3 skin toxicity and low magnesium levels, among others) and was controlled with supportive care (topical and systemic antibiotics, and steroids), dose delays, and reductions.</p><p>In this research article, Tabernero and colleagues also discussed their preclinical experiments which helped them establish that Sym004 could make colorectal cancer cells overcome acquired resistance to cetuximab.</p><p>This study was funded by Symphogen A/S and Merck KGaA. Tabernero is a consultant/advisory board member for Amgen, Imclone, Lilly, Merck KGaA, Millennium, Novartis, Roche, Sanofi, Celgene, Chugai, Taiho, and Symphogen A/S.</p></div>
Prolonged Statin Use May Lower Risk of Lung Cancer Death11673985/1/2015 1:49:02 PM Releases/AllItems.aspx726False2015-05-01T04:05:00Z<div class="ExternalClass8FBD88955E374810994D638C313395B2"><p>PHILADELPHIA — Lung cancer patients who used statins in the year prior to a lung cancer diagnosis or after a lung cancer diagnosis had a reduction in the risk of death from the disease, according to a <a href="http&#58;//" target="_blank">study</a> published in <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>, a journal of the American Association for Cancer Research.<img alt="Chris Cardwell, PhD" src="/PublishingImages/Cardwell_Chris_150x200.jpg" style="margin&#58;0px 10px;vertical-align&#58;auto;float&#58;right;" /></p><p>“Our study provides some evidence that lung cancer patients who used statins had a reduction in the risk of death from lung cancer,” said <a href="http&#58;//;ns=df326e83e77effd6e634341fc446ca91aa6cdaa74c554a90d03235a83502e04d" target="_blank">Chris Cardwell, PhD</a>, a senior lecturer in medical statistics at the Centre for Public Health at Queen’s University Belfast in Northern Ireland.</p><p>“The magnitude of the association was relatively small and, as with all observational studies, there is the possibility of confounding—meaning that simvastatin [a type of statin] users may have differed from simvastatin nonusers in other ways that could have protected them from death from cancer, for which we could not correct. However, this finding is worthy of further investigation in observational studies,” Cardwell explained.</p><p>“If replicated in further observational studies, this would provide evidence in favor of conducting a randomized, controlled trial of simvastatin in lung cancer patients,” Cardwell added.</p><p>Cardwell and colleagues used data from nearly 14,000 patients newly diagnosed with lung cancer between 1998 and 2009 from English cancer registry data. They gathered the patients’ prescription records from the U.K. Clinical Practice Research Datalink and mortality data up to 2012 from the Office of National Statistics.</p><p>Among patients who survived at least six months after a diagnosis, those who used statins after a lung cancer diagnosis had a statistically nonsignificant 11 percent reduction in lung cancer-specific deaths. Among those who used at least 12 prescriptions of statins there was a statistically significant 19 percent reduction in lung cancer-specific deaths, and among those who used lipophilic statins such as simvastatin there was a 19 percent reduction in lung cancer-specific deaths as well.</p><p>Among all patients in the study, those who used statins in the year before a lung cancer diagnosis had a statistically significant 12 percent reduction in lung cancer-specific deaths.</p><p>Cardwell noted that the outcomes were not different between non-small cell lung cancer&#160; patients and small cell lung cancer patients in this study.</p><p>“We hope to conduct a similar analysis in a large cohort of lung cancer patients from Northern Ireland,” Cardwell added.</p><p>This study was funded by the Health and Social Care Research and Development Division of the Public Health Agency of Northern Ireland. Cardwell declares no conflicts of interest.</p></div>
Lifetime Intense Physical Activity May Lower Risk for Non-Hodgkin Lymphoma11674225/1/2015 1:52:51 PM Releases/AllItems.aspx727False2015-05-01T04:05:00ZPrior studies show physical activity reduces risk for colon cancer and breast cancer<div class="ExternalClassE5A96D9CE18C4FA69DD67C454BBD4BED"><p>PHILADELPHIA — Performing vigorous physical activity over one’s lifetime may lower risk for non-Hodgkin lymphoma (NHL), according to a <a href="http&#58;//" target="_blank">study</a> published in <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>, a journal of the American Association for Cancer Research.<img alt="Terry Boyle, PhD" src="/PublishingImages/Boyle_Terry_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>“In this case-control study, we found that the most physically active participants had a lower risk for NHL than the least active participants. We found that vigorous-intensity physical activity in particular, such as activities that increase breathing and heart rates to a high level, was the most effective at lowering risk,” said <a href="http&#58;//" target="_blank">Terry Boyle, PhD</a>, a postdoctoral fellow in the Department of Cancer Control Research at the B.C. Cancer Agency and the School of Population and Public Health at the <a href="http&#58;//" target="_blank">University of British Columbia</a> in Canada.</p><p>“We know that being physically active reduces the risk of colon cancer and breast cancer, and also leads to a range of other physical and mental health benefits. Our findings suggest that people who do vigorous physical activity may also have a lower risk for NHL,” Boyle added.</p><p>Study participants who were in the higher (second, third, and fourth) quartiles of vigorously intense physical activity performance in their lifetimes had about 25 percent to 30 percent lower risk for NHL, compared with those who were in the lowest (first) quartile of vigorously intense physical activity. Physical activity was not associated with greater benefit for any specific age group. </p><p>Boyle and colleagues used data from a case-control study conducted between 2000 and 2004 in British Columbia (BC), which recruited 820 NHL patients (59 percent men) of various ages from the B.C. Cancer Registry and 848 randomly selected controls matched for age, gender, and residential location, from the Client Registry of the British Columbia Ministry of Health. </p><p>Information on demographics and various risk factors for NHL, including lifetime recreational physical activity, was collected using a questionnaire. Participants were asked to record the average number of days per week and average number of hours per day they performed mild, moderate, or vigorous physical activity for each decade of life.</p><p>The researchers assigned a metabolic-equivalent (MET) value to the different types of physical activity, and calculated the average number of MET-hours per week of physical activity for each participant’s lifetime, taking into account both the duration and intensity of physical activity.</p><p>“Currently, there isn’t enough research on this topic to be able to confidently say that being physically active reduces the risk of non-Hodgkin lymphoma, so we are planning to pool data from several studies to investigate this topic further,” Boyle said. “We know that different types of NHL may have different risk factors, so we are also planning to investigate whether physical activity influences the risk for different types of NHL in different ways.”</p><p>This study was funded by the Canadian Cancer Society and the Canadian Institutes of Health Research. Boyle is funded by the Canadian Institutes of Health Research, the Michael Smith Foundation for Health Research, the Killam Trust, and the Australian National Health and Medical Research Council. Boyle declares no conflicts of interest.</p></div>
American Association for Cancer Research Recognizes 2015 Research Grantees at Annual Meeting11135144/22/2015 3:55:53 PM Releases/AllItems.aspx725False2015-04-22T12:00:00Z<div class="ExternalClassF2DE3F775A1340F2BB337DEA5D9AC9BF"><p class="ExternalClass6E40AD35EF11426ABCCC78380D2B3D07">​PHILADELPHIA — The American Association for Cancer Research (AACR) honored its new grantee recipients at the AACR Annual Meeting 2015, which was held in here, April 18-22. The AACR is proud to welcome this newest class of 2015 grantees to a long and distinguished list of dedicated scientists who have been selected as AACR grant recipients.&#160; </p><p class="ExternalClass6E40AD35EF11426ABCCC78380D2B3D07"><strong>Fellowships</strong>&#58; <br><span style="text-decoration&#58;underline;">2015 AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship</span></p><div class="ExternalClass6E40AD35EF11426ABCCC78380D2B3D07"><ul><li><strong>Xiaoyang Zhang, PhD,</strong> Dana-Farber Cancer Institute, Boston<br>“To study the role of MGA loss-of-function mutations in lung adenocarcinoma”<br></li></ul></div><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 AACR Anna D. Barker Basic Cancer Research Fellowship</span></p><ul><li><strong>Aaron J. Huebner, PhD,</strong> Massachusetts General Hospital, Boston<br>“Determining the role of Sox2 in synovial sarcoma”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 AACR Basic Cancer Research Fellowships</span></p><ul><li><strong>Ling Cai, PhD,</strong> The University of Texas Southwestern Medical Center, Dallas<br>“Systematic interrogation of metabolism in non-small cell lung cancer”</li><li><strong>Chao Dai, PhD,</strong> Dana-Farber Cancer Institute, Boston<br>“Targeting the SMAD4 tumor suppressor in pancreatic cancer”</li><li><strong>Benjamin Delatte, PhD,</strong> La Jolla Institute for Allergy &amp; Immunology, San Diego <br>“Deciphering the roles of TET2 and TET3 in leukemogenesis”</li><li><strong>Laurent Fattet, PhD,</strong> University of California, San Diego<br>“Regulation of EMT and tumor invasion&#58; Twist1 mediates mechanosensing of ECM”</li><li><strong>Jennifer B. Goldstein, MD,</strong> The University of Texas MD Anderson Cancer Center, Houston <br>“Clonal evolution of glioblastoma”</li><li><strong>James P. Mahaffey, PhD,</strong> New York University School of Medicine<br>“Characterizing post-translational modifications of N-Ras”</li><li><strong>Jason J. Northey, PhD,</strong> University of California, San Francisco<br>“Tissue tension promotes stemness and breast cancer aggression”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2014 AACR-Amgen Inc. Fellowships in Clinical/Translational Cancer Research</span></p><ul><li><strong>Daria V. Babushok, MD, PhD,</strong> University of Pennsylvania, Philadelphia<br>“Clonal hematopoiesis and malignant transformation in aplastic anemia”</li><li><strong>Gangadhara Reddy Sareddy, PhD,</strong> The University of Texas Health Science Center at San Antonio<br>“KDM1 inhibition as a novel epigenetic therapy to target glioma stem cells”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2014 AACR-Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer Research</span></p><span style="text-decoration&#58;underline;"></span><ul><li><strong>Frederick H. Wilson, MD, PhD,</strong> Dana-Farber Cancer Institute, Boston<br>“A genomic approach to identify drivers of resistance to ALK inhibition”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2014 AACR-Bristol-Myers Squibb Oncology Fellowship in Clinical/Translational Cancer Research</span></p><ul><li><strong>Maria Gkotzamanidou, MD,</strong> Dana-Farber Cancer Institute, Boston<br>“Modifying H3K27 methylome via UTX and JMJD3&#58; Implications in myelomagenesis”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Colon Cancer Alliance-AACR Fellowship in Young-Onset Colorectal Cancer Research</span></p><ul><li><strong>Kent W. Mouw, MD, PhD,</strong> Dana-Farber Cancer Institute, Boston<br>“Identifying genetic vulnerabilities of hypermutated colorectal tumors”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Colorectal Cancer-Michael’s Mission-AACR Fellowship in Young Onset, Late-Stage Colorectal Cancer Research</span></p><ul><li><strong>Noel F.C.C. de Miranda, PhD,</strong> Leiden University Medical Center, Leiden, Netherlands<br>“Neo-antigen-based therapies for young-onset, late-stage colorectal cancer”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Conquer Cancer Foundation of ASCO/AACR Young Investigator Translational Cancer Research Award</span></p><ul><li><strong>Bob Li, MBBS, MPH,</strong> Memorial Sloan Kettering Cancer Center, New York<br>“Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers&#58; A phase 2 ‘basket’ trial”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 AACR Millennium Fellowships in Lymphoma Research</span></p><ul><li><strong>Maite Alvarez, PhD,</strong> Stanford University, Stanford, California<br>“Improving cancer therapy for lymphoma by preventing NK cell exhaustion”</li><li><strong>Katerina Hatzi, PhD,</strong> Weill Cornell Medical College, New York <br>“Therapeutic targeting of lymphoma self-renewal using LSD1 inhibitors”</li><li><strong>Yuh-Ying Yeh, PhD,</strong> The Ohio State University, Columbus<br>“Investigation of the role of exosomes in chronic lymphocytic leukemia”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 AACR-Millennium Fellowships in Multiple Myeloma Research</span></p><ul><li><strong>Hans C. Lee, MD,</strong> The University of Texas MD Anderson Cancer Center, Houston<br>“Validating novel targets against deletion 17p myeloma”</li><li><strong>Cindy Lin, PhD,</strong> Wistar Institute, Philadelphia<br>“Regulation of multiple myeloma by S100A9 protein”</li><li><strong>Bruno Paiva, PhD,</strong> Universidad de Navarra, Pamplona, Spain <br>“Defining MRD and stem myeloma clones of to understand ultra-chemoresistance”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 AACR-Ocular Melanoma Foundation Fellowship, in honor of Robert C. Allen, MD</span></p><ul><li><strong>Stefan Kurtenbach, PhD,</strong> Miller School of Medicine of the University of Miami<br>“BAP1 loss deregulates neural crest guidance cue signaling in uveal melanoma”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Debbie’s Dream Foundation-AACR Gastric Cancer Research Fellowships</span></p><span style="text-decoration&#58;underline;"></span><ul><li><strong>Eirini Pectasides, MD, PhD,</strong> Dana-Farber Cancer Institute, Boston<br>“Enhancing the efficacy of ERBB2 inhibition in gastric cancer”</li><li><strong>Andrea Zamperone, PhD,</strong> Albert Einstein College of Medicine of Yeshiva University, Bronx, New York<br>“Mechanisms of DNA damage signaling by Helicobacter pylori”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research</span></p><span style="text-decoration&#58;underline;"></span><ul><li><strong>Genevieve C. Kendall, PhD,</strong> University of Texas Southwestern Medical Center, Dallas<br>“Zebrafish modeling of PAX3-FOXO1 driven rhabdomyosarcoma”</li></ul><p><br><strong>Career Development Awards&#58;</strong><br><span style="text-decoration&#58;underline;">2015 AACR-Aflac Inc. Career Development Award for Pediatric Cancer Research </span></p><span style="text-decoration&#58;underline;"></span><ul><li><strong>Branden S. Moriarity, PhD,</strong> University of Minnesota - Twin Cities, Minneapolis<br>“Validation and testing of novel therapeutic targets to treat osteosarcoma”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Breast Cancer Research Foundation-AACR Career </span><span style="text-decoration&#58;underline;">Development Awards for Translational Breast Cancer Research</span></p><ul><li><strong>Sasha Elizabeth Stanton, MD, PhD,</strong> University of Washington, Seattle<br>“Development of a multi-antigen vaccine for breast cancer prevention”</li><li><strong>Fengtian Xue, PhD,</strong> University of Maryland, Baltimore <br>“BCL6-BTB domain inhibitors for triple-negative breast cancer”<br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 AACR-Triple Negative Breast Cancer Foundation Career Development Award for Clinical/Translational Research</span></p><ul><li><strong>Eddy S. Yang, MD, PhD,</strong> University of Alabama at Birmingham<br>“Exploiting TNBC vulnerabilities via rationally combined therapies”</li></ul><p><br><strong>Independent Investigator Awards&#58;</strong><br><span style="text-decoration&#58;underline;">2014 Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research</span></p><ul><li><strong>Fariba Behbod, PharmD, PhD,</strong> University of Kansas Medical Center, Kansas City<br>“Essential role of BCL9 in DCIS progression to invasive breast cancer”</li></ul><p><br><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research</span><br style="text-decoration&#58;underline;"></p><ul><li><strong>Scott André Oakes, MD,</strong> University of California, San Francisco<br>“Unfolded protein response in neuroendocrine tumors” <br></li></ul><p><span style="text-decoration&#58;underline;"></span>&#160;</p><p><span style="text-decoration&#58;underline;">2015 Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer</span></p><ul><li><strong>Eliezer Van Allen, MD,</strong> Dana-Farber Cancer Institute, Boston<br>“Response predictors to PD-1/PD-L1 inhibitors in renal cell carcinoma”</li></ul><p><img src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" alt="" style="margin&#58;5px;" />Follow the AACR Annual Meeting 2015 on Twitter&#58; <a href="https&#58;//;q=%23AACR15&amp;src=typd">#AACR15</a></p></div>
AACR, ABC News’ Dr. Richard Besser Use Twitter’s Periscope to Live Stream “Breakthroughs in Cancer Research” From 2015 Annual Meeting11116394/22/2015 11:53:03 AM Releases/AllItems.aspx724False2015-04-22T11:45:00ZNew Broadcasting Platform Allows Top Cancer Researchers to Engage Hundreds of Followers<div class="ExternalClass554D2A3DF7F04BAFBDF68F44FB74D3EB"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) and Richard Besser, MD, ABC News' chief health and medical editor, joined forces Tuesday afternoon on Besser's Twitter chat to share stories, observations, and significant research from the nation's top cancer researchers in conjunction with the AACR Annual Meeting, held April 18 to 22, in Philadelphia. The chat, called &quot;<a href="https&#58;//" target="_blank">Breakthroughs in Cancer Research</a>,&quot; drew 406 participants who sent more than 2,000 tweets in the space of an hour. It was also streamed live through Twitter's Periscope.</p><p>Periscope is Twitter's new live-streaming video app. Its live feeds can be shot through iPhones and iPads and watched through smartphones, desktops, or laptops, either through the app or on Twitter's website.</p><p>&quot;We are excited to take advantage of this new broadcasting platform to reach new audiences with the revolutionary research at this year's AACR Annual Meeting,&quot; said Rick Buck, senior director of communications and public relations for the AACR. &quot;We interacted with cancer researchers and institutions across the country, cancer patients, survivors, and caregivers in a wholly unprecedented way, and the response, combined with the efforts of the Twitter chat, was overwhelming.&quot;</p><p>A roster of the nation's most prominent leaders in cancer research participated in the Twitter chat, which was hosted by William G. Nelson, MD, PhD, director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, and editor-in-chief of <a href="http&#58;//" target="_blank"><em>Cancer Today</em></a>, the AACR's quarterly magazine for cancer patients, survivors, and their family members and friends.</p><p>Periscope participants were&#58;&#160;</p><ul><li><strong>Jose Baselga, MD, PhD</strong>, AACR president and physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center in New York;</li><li><strong>Carlos L. Arteaga, MD</strong>, AACR past-president and the Donna S. Hall chair in breast cancer research and director of the Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee;</li><li><strong>Lewis C. Cantley, PhD</strong>, AACR Annual Meeting 2015 program chair and the Meyer director of the Sandra and Edward Meyer Cancer Center, the Margaret and Herman Sokol professor in oncology research, and a professor of cancer biology in medicine at Weill Cornell Medical College in New York;</li><li><strong>Raymond DuBois, MD, PhD</strong>, executive director of The Biodesign Institute at Arizona State University in Tempe;</li><li><strong>Thomas J. Lynch, MD</strong>, Richard Sackler and Jonathan Sackler professor of medicine (medical oncology), director of Yale Cancer Center, and physician-in-chief at Smilow Cancer Hospital at Yale-New Haven;</li><li><strong>Emil Lou, MD, PhD</strong>, assistant professor of medicine at the University of Minnesota Medical School in Minneapolis;</li><li><strong>Wafik El-Deiry, MD, PhD</strong>, deputy cancer center director for translational research and the co-leader in molecular therapeutics at Fox Chase Cancer Center in Philadelphia; and</li><li><strong>AnneMarie Ciccarella</strong>, cancer survivor and founder of <a href="http&#58;//" target="_blank">Chemobrain Fog</a>, a leading blog for breast cancer advocates.</li></ul><p>The video content, which will stay on Periscope for 24 hours and is available on the AACR's <a href="https&#58;//" target="_blank">YouTube channel</a>, featured conversations between Nelson and all the thought leaders in an interactive format. Researchers and AACR staff also called out various trending topics on the Twitter chat, and discussed them live with Nelson in front of a Periscope audience.</p><p>&quot;The 2015 Annual Meeting at AACR featured some truly groundbreaking research in immunotherapies and precision medicine, and we were proud to share some of those findings with Dr. Besser's online followers,&quot; said Dr. Nelson. &quot;It was great to leverage this new video technology in conjunction with ABC News to spread the word to our audiences in a powerful way.&quot;</p><p>Follow the AACR Annual Meeting 2015 on Twitter&#58; <a href="https&#58;//;q=%23AACR15&amp;src=typd" target="_blank">#AACR15</a>.</p><p>Follow Dr. Besser's ABC News Twitter chat at <a href="https&#58;//;src=typd" target="_blank">#abcDrBchat</a>.</p><p>&#160;</p></div>
Olaparib–Carboplatin Combination Showed Early Signs of Clinical Activity Against Ovarian and Triple-negative Breast Cancers11005764/21/2015 3:15:54 PM Releases/AllItems.aspx722False2015-04-21T14:35:00ZThe sequence of treatment had no effect on toxicity<div class="ExternalClassB4C67C5DFE2A438DA7EDF6B87AD5507B"><p>​PHILADELPHIA — The order in which olaparib (Lynparza) and carboplatin chemotherapy were administered to patients with recurrent women’s cancers did not significantly alter the side effects experienced by the patients, and the combination therapy showed preliminary signs of clinical activity in these patients, according to data from a <a href="https&#58;//;rank=1" target="_blank">phase I clinical trial</a> presented at the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">AACR Annual Meeting 2015</a>, held here April 18-22. <img alt="Victoria L. Chiou, MD" src="/PublishingImages/Chiou_Victoria_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>“The PARP [poly ADP-ribose polymerase] inhibitor olaparib was recently approved by the FDA for treating women with ovarian cancer who have a germline BRCA mutation,” said Victoria L. Chiou, MD, a medical oncology fellow in the<a href="https&#58;//" target="_blank"> Women’s Malignancies Branch </a>at the National Cancer Institute in Bethesda, Maryland. “Studies to identify treatment combinations that might increase the number of patients benefiting from olaparib are important. We asked the question&#58; What is the best way to deliver combination therapy using olaparib and carboplatin to maximize DNA damage, which likely correlates with antitumor effects, and minimize clinical toxicities.</p><p>“We found that the overall sequence of treatments did not significantly impact the side effects that patients felt,” continued Chiou. “Moreover, we identified a safe drug treatment schedule that also had preliminary activity, known as tumor shrinkage, in women with breast cancer and ovarian cancer. In fact, among women with ovarian cancer on the trial with germline BRCA mutations we saw a 60 percent overall response rate with the combination, which is higher than the approximately 30 percent reported response rate for olaparib treatment of heavily pretreated ovarian cancer patients who have a germline BRCA mutation.”</p><p>Chiou explained that the research team was concerned about their preclinical discovery that olaparib pretreatment before carboplatin led to decreased carboplatin-induced DNA damage in tumor cells carrying BRCA1 mutations and launched the phase I clinical trial to explore whether there was an optimal way to deliver the olaparib/carboplatin drug combination.</p><p>The researchers enrolled 59 patients with recurrent women’s cancers in the clinical trial. Among the patients, 47 had ovarian cancer, 10 had triple-negative breast cancer, one had a uterine carcinosarcoma, and one had endometrial cancer. Twenty-six of the ovarian cancer patients and four of the triple-negative breast cancer patients had a germline BRCA mutation.</p><p>The patients were randomized to one of two treatment arms&#58; in arm A, patients received olaparib before carboplatin in cycle one and carboplatin before olaparib in cycle two; in arm B, patients received carboplatin before olaparib in cycle one and olaparib before carboplatin in cycle two. From cycle three, patients received the same treatment regimen. Toxicity was analyzed at the end of every treatment cycle and response at the end of every two cycles.</p><p>Intra-patient and inter-cohort comparisons showed no significant differences in the frequency of grade 3/4 adverse events. The most common grade 3/4 adverse events were neutropenia and anemia.</p><p>According to Chiou, the most updated results show that olaparib given for seven days, in combination with carboplatin given once every 21 days, demonstrated preliminary clinical activity in heavily pretreated patients with breast and ovarian cancer. Among 54 patients the researchers observed one complete response, which lasted for 23 months in a woman with triple-negative breast cancer, and 24 partial responses, 20 in women with ovarian cancer and four in women with triple-negative breast cancer.</p><p>“We currently have two patients still on study,” Chiou added. “One woman has had a partial response that has persisted more than 19 months and another woman who had stable disease documented at the initial time of abstract submission has since achieved a partial response and has been on the study for more than 12 months.</p><p>“I am excited to share these findings. This clinical trial is part of a larger body of clinical trials being done by the Women’s Malignancies Branch at the National Cancer Institute,” Chiou continued. “Every day, my team is working hard to bring new ideas from the bench to the bedside for treatment of women with breast and ovarian cancer. There is more work to be done. This is just the beginning.”</p><p>This study was supported by funds from the intramural program of the National Cancer Institute, with funding to the Center for Cancer Research under an umbrella Cooperative Research and Development Agreement with AstraZeneca. Chiou was previously a recipient of the AACR-GlaxoSmithKline Outstanding Clinical Scholar award for research on PARP inhibitors in triple-negative breast cancer presented at the AACR Annual Meeting 2014. Chiou declares no conflicts of interest.</p><p><a href="/Documents/15AM_Press_Registration_Form.pdf" target="_blank">Press registration</a> for the AACR Annual Meeting 2015 is free to qualified journalists and public information officers.</p><p><img src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" alt="" style="margin&#58;5px;" />Follow the AACR Annual Meeting 2015 on Twitter&#58; <a href="https&#58;//;q=%23AACR15&amp;src=typd" target="_blank">#AACR15</a></p></div>
New PARP Inhibitor Combo Shows Early Promise for Cancer Patients With and Without BRCA Mutations11004684/21/2015 3:03:25 PM Releases/AllItems.aspx721False2015-04-21T14:30:00Z<div class="ExternalClassADDD005CF5C640128083962C92B2C609"><p>PHILADELPHIA — A combination of two molecularly targeted drugs, olaparib and the investigational agent AZD5363, was safe and yielded responses in patients with a variety of cancer types, including breast, ovarian, and prostate cancers, regardless of BRCA1/2 mutation status, according to data from the <a href="https&#58;//;rank=1" target="_blank">ComPAKT phase I clinical trial</a> presented here at the<a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25"> AACR Annual Meeting 2015</a>, April 18-22. <img alt="Timothy Yap, MD, PhD" src="/PublishingImages/Yap_Timothy_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>“In this investigator-initiated clinical trial, we evaluated for the first time whether it is possible to safely combine the investigational AKT inhibitor AZD5363 with olaparib, a PARP [poly ADP-ribose polymerase] inhibitor recently approved by the FDA [U.S. Food and Drug Administration] for treating advanced ovarian cancer associated with defective BRCA genes,” said <a href="http&#58;//" target="_blank">Timothy Yap, MD, PhD, </a>NIHR BRC clinician-scientist and consultant medical oncologist at <a href="http&#58;//" target="_blank">The Institute of Cancer Research</a> and <a href="http&#58;//" target="_blank">The Royal Marsden NHS Foundation Trust</a> in London, United Kingdom.</p><p>“Here, we are reporting results from the dose-escalation portion of the trial, which showed that it was indeed possible to combine these drugs safely,” continued Yap. “We also observed that several different cancer types responded to the combination, including cancers without BRCA1/2 mutations. These early results are very exciting because preclinical data had suggested that the olaparib and AZD5363 combination had the potential to be effective in a much wider population of patients than just those harboring germline BRCA1/2 mutations.”</p><p>Yap also explained that the ComPAKT clinical trial is, to the best of his knowledge, the first phase I clinical trial using a combination of targeted agents to implement an intrapatient dose-escalation design. The design allowed individual patients to receive up to three predetermined escalating doses of AZD5363 in combination with a fixed dose of olaparib, but only if they were tolerating the drug combination well. “This design allowed us to safely complete the dose-escalation phase with at least six evaluable patients at each dose level, and in two schedules of the combination with just 20 patients in 7.5 months, which is unprecedented,” said Yap.</p><p>Of the 20 patients enrolled in the dose-escalation portion of the clinical trial, nine had germline BRCA1/2 mutations. The patients had a variety of cancer types including advanced breast, ovarian, prostate, colorectal, cervical, pancreatic, uterine, and bladder cancers; mesothelioma; and gastrointestinal stromal tumors.</p><p>According to Yap, since the abstract was submitted, there are now four confirmed <a href="http&#58;//" target="_blank">RECIST</a> partial responses, including in a patient with BRCA1/2 wild-type ovarian cancer, two patients with BRCA1/2-mutant breast cancer, and a patient with BRCA1-mutant ovarian cancer. Two patients had ongoing, prolonged RECIST disease stabilization, including a patient with BRCA1/2 unknown breast cancer at six months and a patient with peritoneal mesothelioma at one year with tumor-marker reduction, who had previously responded before developing disease progression on treatment with a PI3K/mTOR inhibitor. One patient with BRCA1/2-mutant advanced prostate cancer also continues to have a sustained response radiologically on MRI and by prostate-specific antigen <a href="http&#58;//" target="_blank">Prostate Cancer Working Group 2</a> response criteria at 11 months.</p><p>Based on tolerability, the researchers established that the recommended phase II combination dose was 640 milligrams of AZD5363 twice a day for two days each week, plus 300 milligrams of olaparib twice a day. The most commonly observed side effects were nausea, vomiting, fatigue, diarrhea, and anemia. “We are currently assessing the drug combination at the recommended phase II combination dose in two different cohorts of patients within the dose-expansion phase of the trial,” said Yap.</p><p>The ComPAKT trial is part of the Combinations Alliance jointly supported by Cancer Research U.K., AstraZeneca, and the Experimental Cancer Medicine Center network. It is co-sponsored by The Institute of Cancer Research (ICR) and The Royal Marsden and received research funding from the NIHR Biomedical Research Center at The Royal Marsden and the ICR. Yap received funding for this clinical trial from AstraZeneca and is supported by the NIHR Biomedical Research Center.</p><p><a href="/Documents/15AM_Press_Registration_Form.pdf" target="_blank">Press registration</a> for the AACR Annual Meeting 2015 is free to qualified journalists and public information officers.</p><p><img src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" alt="" style="margin&#58;5px;" />Follow the AACR Annual Meeting 2015 on Twitter&#58; <a href="https&#58;//;q=%23AACR15&amp;src=typd" target="_blank">#AACR15</a></p></div>